Skip to main content

Philip Boudreau

Equibles does not estimate personal net worth.

Get an email with a short summary when Abbott Laboratories publishes a filing, an earnings call transcript or a press release.

Get ABT alerts

About Philip Boudreau

Philip Boudreau is recorded as CFO at Abbott Laboratories (ABT). The proxy statement of Abbott Laboratories reports total compensation of $9,090,636 for Philip Boudreau in fiscal 2025, including a base salary of $974,231. Disclosed compensation is on record for 3 fiscal years. Philip Boudreau has spoken on 7 earnings calls across 1 company, most recently for Abbott Laboratories on October 21, 2026. Abbott Laboratories is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Abbott Laboratories includes Robert B. Ford (CEO, Chairman and Board Member), Philip P. Boudreau (CFO), Robert E. Funck, Jr. (CFO) and 7 others.

Philip Boudreau on recent calls

“Let me begin my remarks with an overview of some of the key aspects of our planning process for the separation. The new nutrition company will become a publicly traded company through a planned tax-free distribution to Abbott shareholders.”
CFO, Abbott Laboratories Q3 FY2026 Earnings Call ·
“Mike mentioned earlier, please note that all references to sales growth rates, unless otherwise noted, are on a comparable basis.”
CFO, Abbott Laboratories Q2 FY2026 Earnings Call ·
“And then I'll turn over the call to Phil. Of the March 23rd close of our acquisition of Exact Sciences, our first quarter financial results include the results of the Exact Sciences business from the close date through the end of the quarter.”
CFO, Abbott Laboratories Q1 FY2026 Earnings Call ·
“As Mike mentioned earlier, unless otherwise noted, are on an organic basis. Quarter results, sales increased 3.8% when excluding COVID testing sales.”
CFO, Abbott Laboratories Q4 FY2025 Earnings Call ·
“And growth of 8% in point of care diagnostics was driven by growing adoption of two first-of-a-kind tests. Our point of care concussion test and a high sensitivity troponin test which allows for earlier and more accurate detection of a heart attack.”
CFO, Abbott Laboratories Q3 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Abbott Laboratories

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Abbott Laboratories (ABT) $974,231 $9,090,636
2024 Abbott Laboratories (ABT) $884,039 $8,225,746
2023 Abbott Laboratories (ABT) $513,943 $3,317,182

Recent activity